Ad Block Detected

iSpot measures impressions and the performance of TV ads. As such, our content is blocked by ad blockers. Please consider disabling your ad blocker on this site to ensure the best user experience.

Continue To Site >>
NBCU Accelerates Path to Alternative Currencies with iSpot. Read More>
We're Sorry This spot has been removed at the request of the advertiser

Gold Shield Group TV Spot, 'Type-2 Diabetes Medication Side Effects'

National Airings
πŸ”’
First Airing
πŸ”’
Last Airing
πŸ”’
Creatives
πŸ”’
Recently Aired On
πŸ”’
Est. Spend
πŸ”’
TV Impressions
πŸ”’
National Impressions
πŸ”’
Local Impressions
πŸ”’

There’s a Better Way to Measure TV & Streaming Ad ROI

Screenshot of product dashboard
  • Real-Time Ad Measurement Across Linear and CTV
  • TV Ad Attribution & Benchmarking
  • Marketing Stack Integrations and Multi-Touch Attribution
  • Real-Time Video Ad Creative Assessment
Get a Demo Today

Gold Shield Group announces that various medications such as Invokana, Invokamet, Jardiance and Farxiga are linked to an increased risk of toe, leg and foot amputations. Type-2 Diabetics who suffered serious side effects after taking these medications are encouraged to call and file a claim.

Advertiser
Gold Shield Group
Advertiser Profiles
Facebook, Twitter, YouTube
Songs - Add
None have been identified for this spot
Phone
888-435-7861
Mood
Informational
Actors - Add
None have been identified for this spot.
Screenshots
View All Screenshots